Regulatory changes and promising starts ups are fueling demand for outsourced services in China â and as venture capital flows into the country, the pace of innovation is expected to accelerate, says STA Pharmaceutical. https://www.outsourcing-pharma.com/Article/2017/12/07/Chinese-R-D-sector-takes-significant-step-as-outsourcing-demand-increases
The factors shaping the healthcare landscape in emerging markets require pharma to take a different approach to how it works in more developed economies. https://pharmaphorum.com/views-and-analysis/healthcare-emerging-markets/
As Health Care Industry is projected to grow by 17% (compounded annual growth rate) by 2020; startups are attempting to overcome problems such as poor health infrastructure, low levels of insurance, and rural vs urban disparity that are plaguing health services in India. https://www.forbes.com/sites/krnkashyap/2017/09/25/how-startups-are-trying-to-overcome-indias-healthcare-challenges/
SAN DIEGO, July 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequ… http://www.prnewswire.com/news-releases/trovagene-announces-agreement-with-novogene-for-nextcollect-in-china-300486641.html
Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical. http://www.outsourcing-pharma.com/Clinical-Development/China-FDA-changes-will-speed-up-approval-process-says-CRO
MUMBAI (Reuters) – India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.
China is one of the largest generic drug markets in the world. As part of the drug approval reform, the ongoing generic consistency evaluation (GCE) is likely to have significant, long-lasting impacts on the market landscape, drug pricing and generic…By: Allen & Overy LLP http://www.jdsupra.com/legalnews/generic-consistency-evaluation-in-china-27347/
CFDA announces draft guidelines that would allow Phase I trials in China to encourage simultaneous development alongside global trials. http://www.biopharmadive.com/news/china-drug-trials-manufacturing-generics-cfda/439487/
Lung cancer treatment becomes first medicine to pass through the country’s Priority Review pathway http://www.pmlive.com/pharma_news/az_gets_rapid_approval_in_china_for_tagrisso_1190097
The annual review of drug prices will see the price of drugs, on the National List of Essential Medicines, increase by just under 2%. The Indian Government has strict measures to control the pricing of drug prices, something that the Indian pharmaceutical industry has found increasingly difficult, with the latest price increases set to bring medicines in-line with inflation.
read more http://www.pharmafile.com/news/513643/drug-prices-set-increase-essential-medicines-list-india